The Biotech Stock To Buy Now
Could this biotech bet bank you 1,700% profit?Contributed by Raging Bull
Big pharma isn't what it use to be and investors are wondering what the future holds for the Goliaths of the industry.
Kyle Dennis, one of the most well known up and coming traders, saw this shift happening when others didn't. Years ago, he began to place a heavy emphasis on small-cap biotech stocks he saw enormous upside for as they approached catalyst dates during their drug approval process.
"These smaller companies are on the verge of breakthroughs every month and there is untapped potential that no one else seems to be looking at. Everyone is so concerned with the likes of Pfizer (PFE), Johnson&Johnson (JNJ), Novartis (NVS)... They have blinders on. They are oblivious to the success of smaller biotech companies, because their stubbornness is leaving them narrow-minded."
However, there are some that predicted the same thing that Kyle has-Steve Cohen.
Cohen saw what was happening recognizing the potential.
He took a large stake in Celator (CPXX) which had a focus on cancer. The stock went from $1.68 to $30.25 per share as it was bought out by Jazz Pharmaceuticals.
A whopping 1700% gain in only 6 1/2 weeks in 2016.
"It's funny. People often underestimate these small-caps or just choose to avoid them completely. They are the backbone of this industry, and you can be certain that buyouts will increase and big pharma will be looking to acquire more companies, especially as they report positive data."On his radar next is another cancer stock that shows promise just as Celator did.
Others are finally starting to take notice of the changes in the biotech industry.
To Kyle Dennis, however, this is nothing new. He's been stealing profits from large hedge funds by focusing on companies that are overlooked and finding them before others piggyback. Kyle, himself, is a first mover and innovator in the biotech trading space.
He's identified his next stock that he believes has Celator-like profit potential.
Act before June 5th, and click here to view the report !
This is a sponsored advertisement. Paid advertisements appear in Schaeffer's Investment Research, Inc. (SIR) publications, including print and other digital formats. Schaeffer's Research does not endorse or evaluate the advertised product, service, or company, nor any of the claims made by the advertisement. Advertisers making claims are expected to have research data that substantiates these claims and the research or citation is to be made available on the vendor's website or, where proprietary interests exist, be made available upon request. Schaeffer's Research does not claim the research is relevant to the claim nor not verify the validity of the research. Advertising does not influence editorial decisions or content. Schaeffer's Research reserves the right to refuse, reject, or cancel any ad for any reason at any time without liability. Please contact Schaeffer's Research Marketing Solutions to request more information.